With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.
Many of the currently available oral anti-diabetic agents have clinically relevant cardiovascular effects. This expert review concludes that optimal approach to the reduction of cardiovascular risk in diabetic patients should focus on aggressive management of the standard cardiovascular risk factors rather than purely on intensive glycemic control.
Xu J & Rajaratnam R. Cardiovasc Diabetol 2017;16:18. doi:10.1186/s12933-017-0499-5
The authors discuss the prevalence of obesity and type 2 diabetes in children and adolescents and summarize published studies on the safety and effectiveness of antihyperglycemic medications in this population.
Akhlaghi F et al. Clin Pharmacokinet 2017; 56: 561–571. doi:10.1007/s40262-016-0472-6
The review discusses pharmacological therapy for gestational diabetes, dealing with safety and efficacy, for both fetal and maternal morbidity consequences; as well as failure and success in establishing appropriate metabolic and glucose control.
Bergel R et al. Curr Diab Rep 2016; 16: 118. doi:10.1007/s11892-016-0802-y